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Overview
The etiology of Parkinson disease (PD) involves both genetic
susceptibility and environmental exposures. In particular, coffee
consumption is inversely associated with PD but the mechanisms
underlying this intriguing association are unknown. According to a
recent genome-wide gene–environment interaction study, the
inverse coffee–PD association was two times stronger among
carriers of the T allele of SNP rs4998386 in gene GRIN2A than in
homozygotes for the C allele. We attempted to replicate this result
in a similarly sized pooled analysis of 2,289 cases and 2,809
controls from four independent studies (Denmark, France, Seattle-
United States (US), and Rochester-US) with detailed caffeinated
coffee consumption data and rs4998386 genotypes. Using a variety
of definitions of coffee drinking and statistical modeling tech-
niques, we failed to replicate this interaction. Notably, whereas in
the original study there was an association between rs4998386 and
coffee consumption among controls, but not among cases, none of
the datasets analyzed here indicated an association between
rs4998386 and coffee consumption among controls. Based on
large, well-characterized datasets independent from the original
study, our results are not in favor of an interaction between
caffeinated coffee consumption and rs4998386 for PD risk and
suggest that the original finding may have been driven by an
association of coffee consumption with rs4998386 in controls. The
next years will likely see an increasing number of papers
examining gene–environment interactions at the genome-wide
level, which poses important methodological challenges. Our
findings underline the need for a careful assessment of the findings
of such studies.
Introduction
Genome-wide association studies (GWAS) have identified
thousands of genetic risk variants for common diseases, which
typically explain only a small proportion of the underlying
heritability [1]. Unexplained or missing heritability could be
partly due to gene–environment interactions. PD is a good
example of a disease for which numerous susceptibility loci [2] and
putative risk or protective environmental factors [3] have been
identified and may interact. Among environmental factors, there is
robust epidemiological evidence that coffee consumption is
inversely associated with PD independently of smoking [4].
Caffeine is hypothesized to account for this association because
it is an adenosine A2A-receptor antagonist, and this family of
agents has been shown to be neuroprotective and attenuate loss of
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dopaminergic neurons in animal models of PD [5]; however, other
explanations for this association, including reverse causation or
confounding, cannot be discarded.
A recent genome-wide gene–environment interaction study in
PD (testing 811,597 single nucleotide polymorphisms [SNPs] across
1,458 cases and 931 controls) used a joint test of marginal
association and gene–environment interaction [6], followed by
analyses stratified by coffee consumption, to identify modifiers of the
coffee-PD association [7]. The inverse association between coffee
and PD was about two times stronger among carriers of the rare T
allele of rs4998386 in GRIN2A than in homozygotes for the major
C allele (odds ratio (OR) for interaction, ORinteraction = 0.52,
p = 461023). This finding was replicated in a pooled analysis of
three independent US datasets (1014 cases, 1917 controls;
ORinteraction = 0.48, p = 5610
24). The authors concluded that the
inclusion of coffee consumption in their analyses to test for an
interaction with rs4998386 allowed them to uncover one of the most
important PD susceptibility genes, not previously identified in
GWAS due to its small overall effect. GRIN2A encodes a subunit of
the N-methyl-D-aspartate (NMDA) glutamate receptor and regu-
lates excitatory neurotransmission in the brain. The authors
considered it to be biologically plausible that GRIN2A plays a role
in PD through an interaction with caffeinated coffee and suggested
that GRIN2A genotypes may be a useful biomarker for pharma-
cogenetic studies on prevention and treatment in PD.
The study by Hamza et al. [7] represents one of the first
published attempts to identify gene–environment interactions at a
genome-wide scale, a challenging task given the requirement of
very large sample sizes with exposure data [8]. The results from
this study are of great interest as they may provide insight into the
PD–coffee association and thus the underlying pathophysiology of
PD. Analyses of gene–environment interactions can be performed
through a variety of approaches [8], and, to better understand the
findings presented by Hamza et al. [7], we performed a re-analysis
of their data by examining the association between coffee and
rs4998386 separately in cases and controls (Table S1). We found a
strong positive association in controls between rs4998386-T and
heavy coffee drinking (OR = 1.48, 95% CI = 1.23, 1.78,
p = 361025), thus suggesting that GRIN2A-rs4998386-T is
associated with an increased likelihood of drinking coffee among
persons free of PD. On the contrary, among PD cases, heavy
coffee drinking tended to be less frequent in carriers of the
rs4998386-T allele, but this association was not statistically
significant (OR = 0.82, 95% CI = 0.65, 1.03, p = 0.08). Therefore,
it appears that the interaction between rs4998386 and coffee
consumption was in part explained by a positive association
between the rs4998386-T allele and coffee consumption among
controls, but not among PD cases.
Because of the well-described constraints of genome-wide gene–
environment interaction analyses [8] and of this somewhat
unusual pattern of gene–environment interaction, our objective
was to replicate these findings by pooling data from four
independent and well-characterized studies, three of them
population-based, which had collected detailed coffee data.
Results
Our analyses comprised 2,289 cases and 2,809 controls with
complete data on coffee consumption, GRIN2A-rs4998386, and
ever smoking. Rs4998386 genotypes were in Hardy-Weinberg
equilibrium (HWE) in controls from each dataset (p$0.05) and the
frequency of the T allele was similar in controls across all studies
(ranging from 8.7% to 11.8%). Rs4998386 was not associated with
PD in any of the four datasets (Table S2). Danish participants had
the highest level of coffee drinking. Ever coffee drinking was
statistically significantly inversely associated with PD in the French
and Danish datasets; in the Seattle-US dataset, PD cases were less
frequently heavy coffee drinkers than controls, and there was no
statistically significant association of coffee drinking and PD in the
Rochester-US dataset (Table S2). Ever smoking was inversely
associated with PD in all studies (Table S2). In pooled marginal
association analyses of the French, Danish, and Seattle-US studies,
rs4998386 showed no evidence for association with PD risk while
ever coffee drinking was inversely associated with PD, showing a
dose-response relation for all coffee variables (Table S3).
Table S4 shows the cross-tabulation of rs4998386 and coffee
drinking by case-control status and dataset. Regardless of the
definition of coffee drinking, there was no consistent significant
departure from multiplicative effects of rs4998386 and coffee
drinking in any of the individual datasets (Table 1, Table S5). In
pooled analyses of the French, Danish, and Seattle-US datasets
(Table 1), the inverse association with ever coffee drinking was
stronger among CT+TT carriers (OR = 0.73/1.32 = 0.55) com-
pared to CC carriers (OR = 0.77), but the difference was not
statistically significant (ORinteraction = 0.72, p = 0.18). In analyses
based on quantitative characteristics of coffee drinking, there was
no evidence of statistically significant interactions, except for the
category of 130–200 cupyears of coffee consumption (p = 0.038):
the association with cupyears was stronger among CT+TT
carriers (OR = 0.52/1.33 = 0.39) compared to CC carriers
(OR = 0.70). Analyses based on the Rochester-US dataset and
pooled analyses of all datasets revealed no statistically significant
interactions. Analyses using the same approach to categorize
coffee drinking as Hamza et al. [7] revealed no statistically
significant interactions, except for participants from the Rochester-
US dataset in the second quartile of cupyears; however, this result
was only based on seven cases and 23 controls, this pattern was not
apparent in the other studies, and there was no evidence of
interaction at higher consumption levels (Table S6). In addition,
interaction ORs with heavy coffee drinking tended to be greater
than one, whereas Hamza et al. [7] reported interaction ORs
smaller than one (Table S6). Pooled analyses of the French,
Danish, and Seattle-US data using the empirical Bayes approach
yielded results consistent with those of our main analyses;
compared to the traditional case-control analysis, interaction
ORs were generally closer to one and p-values greater (Table S7).
We found similar results in sensitivity analyses when excluding
TT homozygotes, adjusting for packyears of smoking (2140 cases,
2602 controls) or Mini-Mental State Examination (MMSE) (686
cases, 1,100 controls), or upon stratification by sex, median disease
duration (,5 versus $5 years), and median age (#70 versus .70
years) (data not shown). In addition, in the Seattle-US dataset,
there was no interaction between rs4998386 and total caffeine
intake from seven food and beverage sources.
Case-only analyses of the association between rs4998386 CT-
TT genotypes and coffee consumption showed no evidence of
association regardless of the coffee definition (Table 2). Table 3
shows the same set of analyses in controls. While there was no
statistically significant association between rs4998386 and coffee,
OR estimates tended to be greater than one.
Taken altogether, these findings are not in favor of an
interaction between rs4998386 and coffee drinking for the risk
of PD.
Discussion
In this large data pooling effort across multiple sites in the US
and Europe, we found no evidence of an interaction between
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coffee intake and GRIN2A-rs4998386 in PD as previously
reported [7], even though we included a similar number of cases
and controls as the replication phase and more than twice as many
participants as the discovery phase of the original study [7]. We
performed extensive sensitivity analyses, in which we considered
alternative definitions of coffee consumption, applied different
statistical approaches, and performed stratified analyses that
demonstrated the robustness of our lack of replication of the
interaction between coffee intake and GRIN2A-rs4998386 in PD.
There are several possible explanations for our lack of
replication. First, one could argue that the approach of Hamza
et al. [7] is not specifically targeted at identifying gene–
environment interactions: for the genome-wide discovery phase,
they used the 2-df Kraft test, i.e., a test that combines marginal
and interaction effects and was originally presented as a ‘‘tool for
large-scale association scans where the true gene–environment
interaction model is unknown’’ [6]. For their replication, Hamza
et al. [7] specifically focused on the rs4998386-PD association
among heavy coffee drinkers, which was genome-wide significant
in their pooled analyses of discovery and replication data
(OR = 0.51, p = 761028); however, the test for the interaction
between rs4998386 and coffee was not genome-wide significant
(OR = 0.51, p = 361025). Second, the interaction reported by
Hamza et al. [7] resulted in part from a highly significant
association between coffee consumption and rs4998386 among
controls. Interestingly, this is the only situation where the case-only
approach is less efficient than traditional case-control studies to
identify gene–environment interactions [9]. The interpretation of
this pattern of association in the Hamza et al. [7] study is not
straightforward: while controls who carried the rs4998386-T allele
were heavier coffee drinkers than noncarriers, there was a
nonsignificant association between rs4998386-T and coffee in
the opposite direction among PD patients, therefore suggesting
that GRIN2A may play a role in coffee drinking behaviour with
opposite effects in healthy subjects and PD cases. In contrast, we
found no association between coffee drinking and rs4998386
among population controls included in the present study. This is
supported by a meta-analysis of GWAS on coffee intake from eight
Caucasian cohorts (n = 18,176) that found no association between
the number of cups of coffee per day and GRIN2A-rs4998386 in
healthy subjects (beta regression coefficient per one T al-
lele = 0.0105, SE = 0.0165, p = 0.52; I2 = 18%, pheterogeneity = 0.41;
personal communication [10]). Third, PD patients included in the
Hamza et al. [7] study were younger than those included in the
present analysis. However, we found no evidence of interaction in
analyses restricted to younger PD patients and controls. Fourth,
Hamza et al. [7] used dataset-specific cutoffs to define coffee
variables; this approach combines participants from separate
datasets with different exposure levels in the same category and the
resulting ORs do not have a simple interpretation. Our results
were sensitive to the way coffee consumption data were
categorized, as interaction estimates from analyses based on our
main definition and those based on Hamza et al. [7] were not
comparable; it is therefore possible that findings from Hamza et al.
[7] may be sensitive to the way coffee data were categorized for
their analyses.
According to our power calculations, our study was well
powered to identify an interaction of the size estimated by Hamza
et al. [7] or even weaker. The case-only approach, a method with
increased statistical power to detect gene–environment interac-
tions compared to traditional case-control analyses, relies on the
assumption of gene–environment independence among controls
[11]. In our study, rs4998386 was not associated with coffee
consumption among controls and the case-only approach also did
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not identify a statistically significant gene–environment interac-
tion; moreover, the interaction estimate was not in the same
direction as reported by Hamza et al. [7]. Although the number of
controls included in the present study was sufficient to detect an
association between rs4998386 and coffee among controls of the
size estimated based on the data from Hamza et al. [7] (Table S1),
it could be argued that it was insufficient to detect a much weaker
association. For this reason, we also implemented an empirical
Bayes method that allows relaxing the gene–environment inde-
pendence assumption while still maintaining increased efficiency
compared to a traditional case-control analysis [12], and we also
failed to detect an interaction using this approach.
The datasets included in the present analysis have considerable
strengths. Notably, three of them were population-based with
controls representative of the underlying population from which
the cases arose. We included participants from various regions
characterized by a wide range of coffee consumption behaviors,
with a particularly high coffee consumption in the study from
Denmark. These studies had a variety of designs and all failed to
confirm the interaction. Most PD patients were clinically evaluated
by movement disorders specialists in a standardized way in three
of the studies. Finally, we used several analytic methods that all
produced consistent results.
There are also limitations to this analysis. Three of the studies
included prevalent PD patients; however, there was no evidence of
interaction in those with shorter disease duration. Patients were
not clinically assessed as part of the study in Denmark; however,
PD patients were followed at neurological centers and an extensive
effort was made to standardize diagnoses based on the review of
the complete medical records [13]. The inverse association
between coffee and PD was weaker in the Seattle-US dataset
than in the European dataset, but this is unlikely to bias interaction
odds ratios [14]. Coffee and PD were not inversely associated in
the Rochester-US dataset, which is likely due to its use of sibling
controls; this design may be less efficient to examine associations
with environmental factors (because of overmatching), but it has
been shown that they provide unbiased estimates of gene–
environment interactions and have, in fact, increased power to
detect them compared to traditional study designs [15]. Finally, we
included only cases and controls of self-reported non-Hispanic
Caucasian race/ethnicity and our analyses were adjusted for and
stratified by the dataset, but we cannot exclude the possibility that
more subtle within-study population substructure may influence
our results. However, it is very unlikely that this may account for
our negative findings for several reasons: (i) The frequency of
rs4998386 genotypes was comparable across all studies. Hence,
the minor allele frequency does not appear to vary substantially
across non-Hispanic Caucasians from different countries. (ii) One
of the four studies included affected PD cases and their unaffected
sibs; this design is not at risk of bias due to population
stratification. (iii) In this paper, our main focus is the estimate of
the GRIN2A-by-coffee interaction. Previous work shows that that
if there is no association between the genetic and the environ-
mental factor within ethnic groups, the unadjusted (for population
Table 2. Association of coffee drinking with the CT-TT genotype of rs4998386 in the GRIN2A gene among Parkinson disease cases.
France, Denmark, Seattle-US Rochester-US Pooled analysis
Coffee OR (95% CI) p OR (95% CI) p OR (95% CI) p
Never 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) -
Ever 1.05 (0.74, 1.48) 0.78 1.49 (0.71, 3.12) 0.30 1.12 (0.82, 1.53) 0.46
Cups per day
Never 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) -
1 cup 1.05 (0.69, 1.58) 0.83 1.10 (0.47, 2.57) 0.83 1.05 (0.73, 1.52) 0.79
2 cups 0.99 (0.67, 1.47) 0.95 2.27 (0.94, 5.52) 0.070 1.13 (0.79, 1.61) 0.52
$3 cups 1.11 (0.76, 1.62) 0.59 1.51 (0.65, 3.53) 0.34 1.19 (0.84, 1.67) 0.33
Global test 0.88 Global test 0.21 Global test 0.76
Cupyears
Never 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) -
[0–65] 1.08 (0.72, 1.61) 0.71 1.28 (0.53, 3.10) 0.59 1.12 (0.78, 1.61) 0.53
[65–130] 0.95 (0.63, 1.42) 0.79 1.19 (0.49, 2.91) 0.71 1.00 (0.69, 1.43) 0.98
[130–200] 0.98 (0.64, 1.48) 0.90 2.33 (0.90, 6.03) 0.08 1.11 (0.76, 2.62) 0.59
.200 1.27 (0.85, 1.92) 0.25 1.77 (0.70, 4.49) 0.23 1.36 (0.94, 1.97) 0.11
Global test 0.43 Global test 0.41 Global test 0.32
Years of coffee drinking
Never 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) -
[0–37] 0.92 (0.61,1.39) 0.69 1.71 (0.67, 4.34) 0.26 1.02 (0.70, 1.48) 0.93
[37–45] 1.22 (0.81,1.82) 0.34 0.12 (0.46, 2.74) 0.81 1.22 (0.85, 1.75) 0.29
[45–53] 0.91 (0.60,1.39) 0.67 0.92 (0.30, 2.79) 0.88 0.94 (0.64, 1.38) 0.75
.53 1.17 (0.76,1.80) 0.47 2.24 (0.82, 6.08) 0.11 1.32 (0.89, 1.94) 0.16
Global test 0.32 Global test 0.31 Global test 0.25
Odds ratios (OR) and 95% confidence intervals (CI) were computed using logistic regression and adjusted for sex, age in quartiles, ever cigarette smoking, and dataset.
ORs compare the odds of carrying the rs4998386-CT or TT genotypes (outcome) in coffee drinkers (exposure) to the odds of carrying the rs4998386-CT/TT genotypes in
never coffee drinkers among cases (France, Denmark, Seattle-US, N = 1974; Rochester, N = 315; pooled analysis, N = 2289).
doi:10.1371/journal.pgen.1004788.t002
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stratification) interaction estimate is unbiased [16]. As there was
no association between rs4998386 and coffee in any of the
datasets, it is therefore unlikely that population substructure has a
major impact on our results.
In summary, our results strongly suggest that GRIN2A-
rs4998386 does not interact with coffee for the risk of PD. Future
studies of PD, coffee consumption, and genes are of continued
interest to improve our understanding of whether the association
between PD and coffee is truly causal, and if so, what are the
underlying pathophysiological mechanisms. Such investigations
may benefit substantially by considering how the interaction
manifests, i.e., whether it is driven by cases or controls. The
coming years will likely see an increasing number of papers on
gene–environment interactions at the genome-wide scale which
pose important methodological challenges. Our findings underline
the need for a careful assessment of the findings of such studies.
Methods
Ethics statement
Written informed consent was obtained from all subjects, and
the study protocol was approved by the UCLA Institutional
Review Board, the Danish Data Protection Agency, the ethics
committee of Copenhagen, the ethics committee of the Pitie´
Salpeˆtrie`re University Hospital, the Institutional Review Boards at
the University of Washington and Group Health Cooperative, and
the Institutional Review Board of the Mayo Clinic (Rochester,
MN).
Subjects
France. A population-based case-control study was per-
formed within a health insurance system (Mutualite´ Sociale
Agricole, MSA). Patients (18–80 years) from five French districts
who were treated for PD were included (2006–2007) [17]. They
were examined by neurologists and PD was diagnosed using
standard criteria [18]. Two controls per case were randomly
drawn from the electronic list of all MSA members and
individually matched on age, sex, and district of residency. The
reference year was the year of PD onset in cases and the same year
in matched controls. The participation rate was similar in cases
(82%) and controls (77%). We excluded 31 cases and 62 controls
without a DNA sample or of non-European ancestry, leaving 300
cases and 598 controls for the analyses.
Denmark. PD patients treated at ten large neurological
centers in Denmark were identified in the Danish National
Hospital Register files (1996–2009), which include information
since 1977 on all hospitalizations in Denmark, and matched on
birth year and sex to 5–10 density sampled controls selected from
the Danish Central Population Registry at time of case identifi-
cation. From among 2,762 putative eligible PD cases, 179 were
excluded from recruitment owing to lack of a PD diagnosis after an
initial medical record review by medically trained research staff
Table 3. Association of coffee drinking with the CT-TT genotype of rs4998386 in the GRIN2A gene among controls.
France, Denmark, Seattle-US Rochester-US Pooled analysis
Coffee OR (95% CI) p OR (95% CI) p OR (95% CI) p
Never 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) -
Ever 1.15 (0.81, 1.64) 0.45 1.46 (0.66, 3.21) 0.35 1.17 (0.85, 1.61) 0.34
Cups per day
Never 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) -
1 cup 1.19 (0.79, 1.81) 0.40 1.49 (0.64, 3.47) 0.35 1.23 (0.85, 1.77) 0.28
2 cups 1.08 (0.73, 1.60) 0.69 1.61 (0.60, 4.32) 0.35 1.11 (0.77, 1.59) 0.57
$3 cups 1.18 (0.80, 1.73) 0.41 1.33 (0.55, 3.26) 0.53 1.18 (0.83, 1.68) 0.36
Global test 0.78 Global test 0.77 Global test 0.71
Cupyears
Never 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) -
[0–65] 1.08 (0.72, 1.62) 0.71 1.31 (0.54, 3.18) 0.55 1.10 (0.77, 1.59) 0.60
[65–130] 1.11 (0.75, 1.67) 0.60 1.56 (0.63, 3.85) 0.34 1.15 (0.80, 1.66) 0.45
[130–200] 1.33 (0.90, 1.97) 0.15 1.98 (0.75, 5.24) 0.17 1.37 (0.96, 1.97) 0.084
.200 1.03 (0.68, 1.55) 0.89 1.11 (0.39, 3.18) 0.84 1.04 (0.71, 1.51) 0.85
Global test 0.37 Global test 0.63 Global test 0.23
Years of coffee drinking
Never 1.00 (Ref.) - 1.00 (Ref.) - 1.00 (Ref.) -
[0–37] 1.13 (0.74, 1.72) 0.57 1.05 (0.37, 2.96) 0.93 1.12 (0.77, 1.65) 0.55
[37–45] 1.30 (0.87, 1.94) 0.20 1.95 (0.80, 4.75) 0.14 1.36 (0.94, 1.95) 0.10
[45–53] 1.14 (0.76, 1.70) 0.54 1.44 (0.51, 4.05) 0.49 1.15 (0.79, 1.66) 0.46
.53 1.05 (0.70, 1.58) 0.81 1.41 (0.48, 4.08) 0.53 1.07 (0.74, 1.56) 0.72
Global test 0.66 Global test 0.56 Global test 0.42
Odds ratios (OR) and 95% confidence intervals (CI) were computed using logistic regression and adjusted for sex, age in quartiles, ever cigarette smoking, and dataset.
ORs compare the odds of carrying the rs4998386-CT or TT genotypes (outcome) in coffee drinkers (exposure) to the odds of carrying the rs4998386-CT/TT genotypes in
never coffee drinkers among controls (France, Denmark, Seattle-US, N = 2494; Rochester, N = 315; pooled analysis, N = 2809).
doi:10.1371/journal.pgen.1004788.t003
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supervised by a movement disorder specialist, leaving 2,583
patients to be contacted. Of these, 497 (19%) declined participa-
tion, and the diagnosis of idiopathic PD could not be confirmed
using standard diagnostic criteria for another 273 putative patients
[13]. The remaining 1,813 idiopathic PD cases provided exposure
data by questionnaire and interview, of whom 1,575 (87%) also
provided DNA samples for genotyping. Out of 3,626 eligible
controls, 1,887 completed an interview and questionnaire and
1,607 (85%) provided a DNA sample. 287 cases and 213 controls
had missing information for either coffee drinking or smoking,
leaving 1,288 cases and 1,394 controls for the analyses. The
reference date for exposure assessment was the occurrence of the
first cardinal (motor) symptom or the first date of PD diagnosis
from the medical records, and controls were assigned the date of
their respective matched cases.
Seattle-US. Newly diagnosed PD cases were identified in a
population-based case-control study conducted in western Wash-
ington State at Group Health Cooperative (GHC), a health
maintenance organization, and the University of Washington
Neurology Clinic in Seattle (1992–2008) [19,20]. All diagnoses
were confirmed by a neurologist or verified by a team of
neurologists by consensus chart review [18]. Cases were enrolled
within four years of diagnosis (most within two years), and all had a
MMSE score $24. Controls were neurologically normal (no
history of multiple sclerosis, Alzheimer’s disease, or other
neurodegenerative disorder, MMSE score $24), enrolled in
GHC, and frequency-matched to cases by sex, age, race and
ethnicity, clinic, and year of GHC enrollment. 386 cases and 502
controls who were non-Hispanic Caucasians with genotyping,
coffee, and smoking data were included in the analyses.
Rochester-US. This family-based dataset consists of 443
discordant sibling pairs, such that each sibling pair has one
member affected with PD and one unaffected. Cases residing in
Minnesota or one of the surrounding states (Wisconsin, Iowa,
South Dakota, and North Dakota) were enrolled (1996–2004) at
the Department of Neurology of the Mayo Clinic (Rochester,
MN). All cases underwent a standardized clinical assessment
performed by a neurologist; PD was diagnosed using standard
criteria [18]. Cases provided a genealogical history, and, when
permitted, available siblings were contacted for a telephone
interview to exclude parkinsonism via a validated screening
instrument. Cases were matched to a single participating sibling
without parkinsonism, first by sex (when possible) and then by
closest age [21]. Exposure data were obtained by direct (or proxy
for incapacitated subjects) interview using a structured question-
naire administered via telephone by trained research assistants
blinded to case-control status [22]. Both genotype and relevant
exposures were available for 315 pairs.
Genotyping
The source of DNA was saliva (Oragene) for France and
Denmark, blood (86%) and buccal specimens (14%) for Seattle-
US, and blood for Rochester-US.
SNP rs4998386 was genotyped in the French (call rate, 97%),
Seattle-US (call rate, 97%) and Danish (call rate, 96%) datasets
using allelic discrimination assays based on TaqMan chemistry
according to the manufacturer’s protocol (Life Technologies, Inc).
For the genotyping of the French samples, six DNA samples from
the PEG dataset included in the study of Hamza et al. [7] were
included on each plate (concordance rate, 100%). For the Danish
samples, each plate included 5% HapMap CEU (Northern/
Western Europe ancestry) control samples (concordance rate,
100%).
The Rochester-US dataset contained individual-level genotype
data from the ‘‘Mayo-Perlegen Linked Efforts to Accelerate
Parkinson’s Solutions (LEAPS) Collaboration’’ [21]. Genotyping
was performed using a Perlegen platform (198,345 SNPs). Data
cleaning was performed with the PLINK toolset v1.07 (http://
pngu.mgh.harvard.edu/,purcell/plink/) as previously described
[2]. Briefly, samples were cleaned on the basis of genotyping
efficiency and quality by excluding all SNPs with a minor allele
frequency (MAF),0.01, missing rates .2%, or HWE violations
(P,161026); samples with genotyping efficiency ,95% were
excluded. This resulted in 149,817 analyzable SNPs (433 PD
cases, 428 controls). rs4998386 was not genotyped and was
imputed as follows: uncovered autosomal SNPs were imputed on a
genome-wide scale from the cleaned dataset using the IMPUTE
program v2.0 (http://mathgen.stats.ox.ac.uk/impute/impute_v2.
html) and the precompiled HapMap 3 (release #2) and 1000
Genomes CEU+TSI (Pilot 1) panels (obtained on June 2nd, 2010).
Individual-level genotypes were assigned according to the geno-
type called with 0.9 or greater posterior call probability, or coded
as missing if the posterior call probability fell below 0.9. Imputed
datasets were cleaned following the same thresholds as outlined
above. The final dataset consisted of 735,746 SNPs (429 PD cases,
427 controls), including rs4998386.
Coffee intake
Analyses were based on caffeinated coffee consumption, as for
three out of the four datasets included in Hamza et al. [7]. All
studies assessed whether participants had ever been coffee
drinkers. The French, Danish, and Rochester-US studies collected
information on the usual number of cups of coffee per day that
participants drank during several periods of life, thus allowing us to
compute an average number of coffee cups per day and a
cumulative number of coffee cupyears (number of cups per day
multiplied by the number of years); only exposures occurring prior
to PD onset in cases or the reference date in controls were
considered. The Seattle-US study collected information on the
typical lifetime number of coffee cups per day, but not on duration
of coffee drinking; we used data from a PD case-control study
conducted in California (PEG) and included in Hamza et al. [7] to
impute average duration of coffee drinking. Among several
covariates (PD disease status, smoking, age, sex, number of coffee
cups per day), the main determinants of duration of coffee
drinking were age and number of coffee cups per day; we used
these covariates to impute duration of coffee drinking using linear
regression for this study.
For our main analyses, we used four different definitions of
coffee intake: (i) never versus ever coffee drinking; (ii) number of
cups per day in four classes (never, 1, 2, $3); (iii) cupyears (never,
[0–65], [65–130], [130–200], .200); (iv) years of coffee drinking
(never, [0–37], [37–45], [45– 53], .53); cutoffs were chosen a
priori, based on the inspection of the distributions of the variables
in each dataset, so that there was a sufficient number of exposed
subjects in each category in all studies.
In sensitivity analyses, we used the same approach as Hamza
et al. [7]: median cupyears was determined among controls
(excluding those with zero intake) in each dataset separately and
used to distinguish light (never, #median) from heavy (.median)
drinkers; in addition, quartiles of cupyears were defined among
controls from each dataset using the full range (from zero to
maximum intake). We did not use this approach as our primary
method, because it combines in the same category participants
from different datasets with different exposure levels and creates
difficulties for the interpretation of results. In addition, never
coffee drinkers may have different characteristics compared to
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coffee drinkers, but are not considered as a distinct category.
Additionally, we performed sensitivity analyses for the Seattle-US
dataset using caffeine intake from seven food and beverage sources
as the exposure variable [23].
Power calculations
Power calculations were performed using the Quanto Software
[24].
Case-control analysis. Based on the following parameters
(minor allele frequency, MAF: 10%; ever coffee drinking: 80%;
marginal genetic OR: 1.0; marginal coffee OR: 0.75; ncases = 2289,
ncontrols = 2809), our study had a power of 98.8% to detect an
interaction OR of 0.5 (as estimated by the original study [7]) at the
0.05 two-sided level; power was still adequate (86.7%) to detect a
weaker interaction OR of 0.6. Assuming a 40% exposure
frequency for heavy versus light coffee drinking, the power to
detect an interaction OR of 0.5 was 99.3% and it was 91.0% to
detect an interaction OR of 0.6.
Case-only analysis. Our study had a power of 99.9% to
detect an interaction OR of 0.5; power was still adequate (85.0%)
to detect a weaker interaction OR of 0.7. If we assumed a 40%
exposure frequency (heavy versus light coffee drinking), the power
to detect an interaction OR of 0.5 was 99.9% and it was 86.6% to
detect an interaction OR of 0.7.
Statistical analysis
Only non-Hispanic Caucasian subjects were included in the
analysis as there were very few subjects from other racial and
ethnic groups in all studies. We checked that rs4998386 genotypes
were in HWE among controls from each dataset using an exact
test (p$0.05). All analyses were first performed independently for
each dataset. For the French, Danish, and Seattle-US studies, we
computed ORs and 95% confidence intervals (CI) using uncon-
ditional logistic regression adjusted for age (in quartiles) and sex;
we broke the matching for the French and Danish studies as some
participants did not provide DNA. For the Rochester-US dataset,
we used conditional logistic regression to take into account the fact
that cases and controls were related. All analyses were also
adjusted for ever cigarette smoking. Second, we obtained pooled
OR estimates for the French, Danish, and Seattle-US studies by
using unconditional logistic regression adjusted for age (in
quartiles), sex, ever cigarette smoking, and dataset; we did not
include the Rochester-US dataset at this stage due to the difference
in study design. Finally, we combined the four studies in a single
analysis by using an approach that allows pooling of individual
data from matched and unmatched case-control studies [25,26].
We examined the marginal association of rs4998386 and coffee
with PD. Since TT homozygotes were very rare (,1% of controls
in all studies), we used a dominant model of inheritance (at least
one T-allele versus none); in sensitivity analyses, we excluded TT-
homozygotes to check for the robustness of our results [7].
To investigate the interaction between rs4998386 and coffee, we
used a variety of approaches. We estimated the individual and joint
effects of rs4998386 (dominant coding) and coffee and performed a
statistical test of interaction by including multiplicative terms
between rs4998386 and each category of coffee drinking in the
models while retaining all respective main effects [27]. A global test
of interaction was performed by comparing the log-likelihood of this
model with that of a model without interaction terms; this approach
is preferable compared to including interactions with linear
continuous variables that may lead to biased interaction estimates
[28]. We tested for interactions on a multiplicative scale as in the
original paper [7]; when at least one exposure is ‘‘preventive’’ (e.g.,
coffee), multiplicative statistical models are appropriate according to
several causal models [29]. Interactions were also estimated through
an empirical Bayes method that allows relaxing the gene–
environment independence hypothesis among controls and is
usually more powerful than the standard analysis [12]; this
approach is only available for unmatched case-control data and
was not implemented for the Rochester-US dataset.
Finally, we studied the association between rs4998386 and
coffee separately among cases and controls using unconditional
logistic regression adjusted for age (in quartiles), sex, ever
cigarette smoking, and dataset. Under the hypothesis of gene-
environment independence among controls (i.e., rs4998386 is
not associated with coffee drinking behavior), a significant
association between rs4998386 and coffee among cases
indicates an interaction. This approach is usually more
powerful than a traditional case-control analysis; however, if
the hypothesis of gene–environment independence among
controls does not hold, interaction ORs are biased and type 1
error is inflated [11].
In sensitivity analyses, we performed analyses stratified by sex.
Since participants included in the present study were on average
older than those included in the original paper [7], we also
performed analyses stratified by median age. We assessed whether
disease duration had an influence on our findings by performing
analyses by disease duration (,5 years, $5 years). We also
checked whether adjusting for MMSE (available for the French
and Seattle-US datasets) or packyears of smoking had an impact
on our findings.
Conditional and unconditional logistic regression and empirical
Bayes analyses were performed with R, v3.01 (R-Foundation for
Statistical Computing, Vienna, Austria).
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